Structure—Activity Relationship of Semicarbazone EGA Furnishes Photoaffinity Inhibitors of Anthrax Toxin Cellular Entry

Michael E. Jung,†‡§ Brian T. Chamberlain,†‡ Chi-Lee C. Ho,§ Eugene J. Gillespie,§ and Kenneth A. Bradley†‡§

†California NanoSystems Institute, ‡Department of Chemistry and Biochemistry, §Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, California 90095, United States

Supporting Information

ABSTRACT: EGA, 1, prevents the entry of multiple viruses and bacterial toxins into mammalian cells by inhibiting vesicular trafficking. The cellular target of 1 is unknown, and a structure—activity relationship study was conducted in order to develop a strategy for target identification. A compound with midnanomolar potency was identified (2), and three photoaffinity labels were synthesized (3–5). For this series, the expected photochemistry of the phenyl azide moiety is a more important factor than the IC50 of the photoprobe in obtaining a successful photolabeling event. While 3 was the most effective reversible inhibitor of the series, it provided no protection to cells against anthrax lethal toxin (LT) following UV irradiation. Conversely, 5, which possessed weak bioactivity in the standard assay, conferred robust irreversible protection vs LT to cells upon UV photolysis. While 3 was the most potent inhibitor of intoxication by LT in the standard assay, it did not provide protection to the cells upon UV photolysis. Conversely, 5, which possesses two fluorine atoms ortho to the azido function, was a poor inhibitor in the standard assay yet provided cells with the most effective irreversible protection against LT upon UV irradiation. These results represent significant progress toward our goal of identifying the cellular target of this series of compounds and highlight useful considerations for photoaffinity labeling studies in general.

Prior to launching the structure—activity relationship study, we confirmed that the intact semicarbazone structure of 1 was the entity responsible for the inhibition of membrane trafficking. In a previous study, semicarbazones derived from aldehyde-based Cathepsin K inhibitors were shown to have poor C==N bond stability, which, along with other evidence, led researchers to conclude that the semicarbazones were functioning as prodrugs delivering a bioactive aldehyde. On the other hand, structurally distinct peptide-semicarbazones were shown to be stable in acidic media, requiring reflux to induce decomposition. In our case, incubating RAW 264.7 macrophages with the semicarbazide (6) and the benzaldehyde component of 1 (both individually and in combination) prior to addition of LT did not prevent toxin-induced cell death.

Received: November 27, 2013
Accepted: December 26, 2013
Published: January 21, 2014

© 2014 American Chemical Society

which indicates that the complete semicarbazone structure is required for bioactivity (Supporting Information, Figure 1). The structure–activity relationship study began by evaluating the importance of the N4-2,6-dimethylphenyl moiety for the bioactivity of 1. Several N-substituted semicarbazides (6, 7a–c) were synthesized by reaction of hydrazine with an intermediate phenyl carbamate, or via direct addition of hydrazine with tert-butyl isocyanate (8). Condensation of these semicarbazides with 4-bromobenzaldehyde proceeded well in all examples, and the desired products (1, 9a–c, and 10) were obtained pure by recrystallization (Scheme 1). The stereochemistry of the semicarbazone double bond is assigned as E based on analogy with known benzaldehyde semicarbazone structures.8–12

Cell viability data demonstrated the critical importance of the 2,6-dimethylphenyl moiety for the inhibition of membrane trafficking [For the less active analogues, precise IC50 values were not determined due to poor solubility above 25 μM. These compounds are characterized by an activity limit (i.e., >12.5 μM, >25 μM) or as “not protective” if no bioactivity was observed up to 25 μM] (Table 1). Thus, compounds lacking this motif (9a, 10, and 11) were not protective, and a 2,6-diethylphenyl moiety (9c) displayed significantly diminished bioactivity (IC50 >12.5 μM). Additionally, the N4-2,4,6-trimethylphenyl analogue 9b was approximately 10-fold less active than 1. Although we did not systematically investigate the activity of analogues with modifications at all the positions of the N4-phenyl ring, these results demonstrate the limited potential for modifications in this position of 1. Examination of the N1-position began with the synthesis and testing of ten compounds prepared from a variety of benzaldehydes (13a–j) (Table 2). The bioactivity supported the hypothesis from preliminary SAR work (i.e., 12) that substitution in the 4-position was critical for potency. Next, nine compounds prepared from 4-substituted benzaldehydes were examined in order to give more detailed characterization.
of that critical position (13k–s). Although no compound from this set was more potent than 1, substitution in this position was found to be generally well tolerated, with 9 of the 13 compounds featuring a benzylidene motif substituted only in the 4-position registering an IC50 between 1 and 4 μM. Five analogues consisting of heterocyclic rings were also synthesized. While 13t–13w did not offer protection to cells challenged with LT, the S-bromophenothiazin-2-ylmethane example (13x) possessed bioactivity similar to that of 1 (IC50 1.7 μM and 1.4 μM, respectively).

The fact that the N1,2,4-trifluoro analogue (13f) was notably more potent than the analogue from 4-fluorobenzaldehyde (13e) (IC50 2.1 μM vs IC50 7.0 μM) led us to examine whether including a fluorine in the 2-position of the N1-ring would similarly augment the potency of 1. Indeed, compound 2 displayed a significant increase in activity (IC50 0.4 μM). Encouraged by this result, we synthesized and tested compounds 13y–13ab, which gave IC50 values that were all larger than the original lead compound 1.

The modifications made to the semicarbazone core are compiled in Scheme 2. The imine bond of 1 could be

effectively reduced to the disubstituted hydrazine derivative (14) using an excess of borane in THF with heating. The compound was not protective at the concentrations tested. The 1-(4-bromophenyl)ethylidene analogue (15) was synthesized by the condensation of the semicarbazide 6 with 4'-bromoacetophenone. This change caused a minor reduction in potency, with 15 showing an IC50 of 2.5 μM (Table 2). The semicarbazone core of 1 could be methylated with high regioselectivity by treatment with iodomethane and K2CO3 in DMF to give 16. Synthesis of 16 via addition of methyl hydrazine to 4-bromobenzaldehyde followed by reaction with phenyl (2,6-dimethylphenyl)carbamate gave a product with identical 1H NMR and 13C NMR spectra and thus confirmed the regiochemistry of methylation at the N1-position. The bioactivity of 16 was not significantly affected compared to that of 1 (IC50 = 2.0 μM and 1.4 μM, respectively). Incorporating a propargyl group into this position by alkylation with propargyl bromide generated 17, which had somewhat impaired bioactivity (IC50 > 12.5 μM).

The thiosemicarbazones (19a–c) were synthesized from N-2,6-dimethylbenzylthiosemicarbazide, 18, and the corresponding benzaldehyde in refluxing ethanol and acetic acid13 (Scheme 3). Substituting the carbonyl of 1 with a thiocarbonyl,

Scheme 3. Synthesis and Bioactivity of 19a–c and 22

19a, had little effect on the potency of the compound (IC50 = 1.5 μM) while exacerbating an already problematic solubility profile. For example, compounds 19b and 19c were poorly soluble at assay concentrations (cLogP: 19a, 5.8; 19b, 6.0; 19c, 6.1; 1, 5.2) and did not return meaningful dose–response curves. A significantly more soluble C==NH compound (22) (cLogP: 3.9–4.0) was elaborated from the S-methylation of (2,6-dimethylphenyl)thiourea,14 20, to give 21, followed by displacement with hydrazine and condensation with 4-bromobenzaldehyde to give the hydrazinecarboximidamide, 22. Unfortunately, the bioactivity of this compound was diminished (IC50 = 13.8 μM).

From the structure–activity relationship data, it was evident that the most effective photoaffinity probe would contain an N1,2,6-dimethylphenyl unit, an unmodified semicarbazone core, and a 4-substituted benzylidene motif at the N1'-position. As the course of phenyl azide photolysis is known to be sensitive to the substituents of the phenyl azide,15,16 three photoaffinity labels were designed. The first, 3, would be predicted by the SAR to provide the highest potency in the in vitro assay. The second, 4, would consist of a simple phenyl azide commonly employed in the biochemical literature.17 The third molecule, 5, would flank the azido group with fluorines, a modification known to give a longer-lived singlet nitrene that can more effectively yield genuine insertion products upon photolysis.18,19

Compounds 3, 4, and 5 were synthesized from 6 and the desired azido-containing benzaldehyde (4-azidobenzaldehyde (25), 4-azido-2-fluorobenzaldehyde (26), and 4-azido-2,3,5,6-tetrafluorobenzaldehyde (27)), in the usual manner. Compound 25 could be obtained from the ethylene acetal of 4-nitrobenzaldehyde via catalytic hydrogenation and diazotization followed by reaction with sodium azide.20 In this study we chose to perform an Ullmann-type coupling with 4-iodobenzyl alcohol (23) and sodium azide14 followed by oxidation to the aldehyde (Scheme 4). This protocol was convenient on the milligram scale and provided access to the previously undescribed 26 from 4-bromo-2-fluorobenzyl alcohol, 24. Compound 27 was synthesized according to a known procedure via an SNAr reaction of sodium azide with pentafluorobenzaldehyde.18
As predicted, 3 and 4 were inhibitors of LT membrane trafficking, with 4 having an IC₅₀ of 2.8 μM and 3 giving an IC₅₀ of 2.2 μM, while 5 was only weakly protective against LT, beginning to show a biological effect at 25 μM. The reversibility of inhibition by 3–5 was confirmed by incubating cells with inhibitor-containing media and then exchanging it for fresh media prior to intoxication with LT. As expected, the arylsemicarbazones could be “washed-out” and there was no cell viability in these experiments upon exposure to LT (Figure 1). Irradiating the cell cultures incubated with 4 and 5 with 5 in the N²-phenyl ring, it is not apparent how such a “clickable” linker could be included into a bioactive photoaffinity version of 1. Nevertheless, the convenience of this approach led us to synthesize compound 28, an N³-propargyl analogue of 4 (Table 2). This compound did not offer any protection to cells at any concentration tested. Accordingly, radiolabeled versions of 5 are being considered as a means of identifying the bound proteins.

In conclusion, we have conducted a structure–activity relationship study that has examined how modifications in the structure of 1 affect the cellular entry of LT. The data indicate a tight and relatively flat SAR, with many of the original structural features of 1 being preferred for bioactivity. Inclusion of a fluorine in the 2-position of the N¹-benzylidene portion appears to be a general strategy for increasing the potency of these arylsemicarbazones and, in the case of 2, improved potency to midnanomolar levels. The photoaffinity probes 3, 4, and 5 were synthesized from azido-containing benzaldehydes. Photolysis of 4 and 5 in the presence of RAW 264.7 cells conferred irreversible resistance to LT and implies that covalent bonds with the cellular target were generated. We are in the process of designing and preparing radiolabeled versions of these compounds to facilitate target identification.

### ASSOCIATED CONTENT

#### Supporting Information

Synthetic procedures and ¹H NMR, ¹³C NMR, and HRMS characterization data for all compounds tested in bioassay. For select compounds, additional characterization includes ¹³C NMR (2, 3, 4, 13x, 14, 15, 16, 17, 19a, 28), FTIR (2–5, 13x, 28), and melting point (2, 13x). NMR spectra are provided for select compounds. Materials and methods for cellular intoxication assays and photolabeling experiments are included. This material is available free of charge via the Internet at http://pubs.acs.org.

### AUTHOR INFORMATION

#### Corresponding Author

*E-mail: jung@chem.ucla.edu.*

#### Notes

The authors declare no competing financial interest.

### REFERENCES


